While I am not over impressed with progens record in developing...

While I am not over impressed with progens record in developing PI88 I believe you are misrepresenting the facts here by importing Avastins recent issues. Avastin's issues are specifically with breats cancer where it is competing for approval with paclotaxel - a very effective drug in it's own right. The issues with avastin appear not to be target related but rather related to the composition of avastin itself. I do not believe that one can draw any conclusion what-so-ever about how PI88 might perform under similar circumstances from this result with avastin. The following link provides a very low tech summary of avastin's current woes: - http://www.nytimes.com/2007/12/04/business/04avastin.html

Avastin is already approved for a large number of indications and is a very effective treatment in many of them.

How PI-88 performs will reflect it's own particular pharmacology and will be a test of the management and board or Progen.IMHO.

As always, form your own opinion